Sonoma Nears Breakeven as Revenue Jumps 60%, But Nasdaq Delisting Risk Looms
SNOA sits 41% above its 52-week low of $0.85.
Summary
Sonoma Pharmaceuticals reported Q1 FY2027 revenue of $6.4M (+60% YoY) and a near-breakeven net loss of $330K, but flagged a new Nasdaq delisting risk over its low market value.
Key Events · Earnings and Guidance · SNOA
-
Revenue Surges 60% to $6.4M
Total revenue hit $6.4 million, up from $4.0 million a year ago, with U.S. sales soaring 141% to $2.4 million on new distributor wins and OTC product demand.
-
Net Loss Narrows to Near Breakeven
Net loss was just $330,000 ($0.09/share) vs. $1.24 million ($0.76/share) last year, driven by higher gross margins (40% vs. 36%) and operating leverage.
-
Cash Runway Extended via $3.5M Equity Raise
A public offering in April 2026 brought in $3.5 million net, boosting cash to $5.3 million. Management says this funds operations for at least 12 months.
-
Nasdaq Delisting Risk from New MVLS Rule
A new Nasdaq rule requires a minimum $5 million market value of listed securities. Sonoma's market cap hovers near that threshold, and failure means immediate delisting with no compliance period.
Analysis · SNOA · Industrial Applications And Services
A dramatic turnaround marks Sonoma's Q1 FY2027: revenue surged 60% to $6.4 million, fueled by a 141% jump in U.S. sales, while the net loss shrank to just $330,000 — a whisper away from profitability. The balance sheet got a lifeline from a $3.5 million equity raise, pushing cash to $5.3 million and funding operations for at least a year. However, a new Nasdaq rule requiring a $5 million minimum market value of listed securities threatens delisting, which would choke off access to capital markets. The company's adjourned special meeting to approve a reverse split — now pushed to August 19 — is the next critical event to watch.
At the time of this filing, SNOA was trading at $1.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.85 to $6.92. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.